From Yahoo Finance: 2025-06-05 23:25:00

Goldman Sachs upgraded Bayer Aktiengesellschaft (OTC:BAYRY) to Buy from Neutral, setting a price target of EUR 33, citing a positive risk/reward profile. Bayer’s strong start to the year included cost discipline in its Crop Science division and growth in its Pharmaceuticals business. Despite a 3% decline in Crop Science sales, Pharmaceuticals sales increased 4%, driven by Nubeqa and Kerendia. Bayer’s EPS in Q1 2025 was EUR 2.49, on track to achieve EUR 4.50 to 5.00 for the year. Bayer operates in Pharmaceuticals, Consumer Health, and Crop Science segments. The potential of BAYRY as an investment is noted, with a recommendation to explore AI stocks for higher returns.



Read more at Yahoo Finance: Goldman Sachs Upgrades Bayer (BAYRY) to Buy